Congress does not pass 'most favored nation' drug pricing law in 2026

Market overview

Pharma leaders oppose the policy, citing concerns about care rationing and free market principles. Republican congressional opposition makes passage unlikely, but industry will remain vigilant.

regulatory prediction market

Implied probability (Yes)

85%

Source: user-generated

More regulatory markets

• Crypto billionaire Harborne faces FCA scrutiny over £5m gift — 55% Yes
• Crypto billionaire Harborne will face FCA scrutiny — 60% Yes
• Crypto billionaire Christopher Harborne’s donation triggers FCA inquiry into funding transparency — 70% Yes
• Crypto billionaire Christopher Harborne will face parliamentary scrutiny over £5m gift — 55% Yes
• Harborne crypto holdings face regulatory scrutiny — 60% Yes
• SEC approves at least 2 new Bitcoin ETFs by Q4 2027 — 75% Yes
• SEC approves Kalshi's crypto futures products by 2026-Q3 — 55% Yes
• Iran's central bank bans crypto mining by 2027 Q1 — 85% Yes

Browse all regulatory markets →